Picard Medical Completes Successful Implant Study for Artificial Heart

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Jun 02 2026

0mins

PMI-4.71%

Explore Agentic TradingLet AI Trade for You

Source: NASDAQ.COM

Successful Study: Picard Medical announced the successful completion of acute in vivo implant studies for the Emperor TAH platform at the University of Arizona and Banner University Medical Centre, marking a significant advancement in artificial heart technology that is expected to drive future clinical applications.
Technological Innovation: The Emperor TAH is designed as a fully implantable artificial heart intended to provide long-term circulatory support for patients with advanced biventricular heart failure, eliminating the need for external pneumatic drivers, thereby enhancing patient quality of life and mobility.
Clinical Performance: Three acute implant procedures were successfully completed in the study, with the Emperor TAH demonstrating stable hemodynamic support across all procedures and no device-related intraoperative failures observed, indicating its reliability and safety.
Market Reaction: Following the announcement, PMI's stock surged by 136.97% in pre-market trading, rising from $0.16 to $0.40, reflecting strong investor confidence in the company's future growth potential.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PMI

About PMI

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Investigation into Picard Medical Shareholder Lawsuit

Jun 04 2026Globenewswire

Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether officers of Picard Medical Inc. breached their fiduciary duties to shareholders, with allegations that the company failed to disclose involvement in a fraudulent stock promotion scheme, potentially harming shareholder interests.
False Promotion Issues: According to a federal securities lawsuit, Picard Medical is accused of being subjected to false promotions on social media, involving impersonated financial professionals, which could severely mislead investor decisions.
Insider Trading Allegations: The investigation reveals that insiders and/or affiliates of Picard may have used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign, raising further concerns about corporate governance.
Disclosure Failures: Picard's public statements and risk disclosures omitted any mention of false rumors and artificial trading activity, which could expose shareholders to significant risks in their investment decisions.

Picard Medical Executives Allegedly Breached Fiduciary Duties

Jun 04 2026Newsfilter

Shareholder Lawsuit Investigation: Kuehn Law, PLLC is investigating whether executives at Picard Medical Inc. breached their fiduciary duties to shareholders, with allegations centered around the company's failure to disclose critical information in a securities fraud case.
False Promotion Exposure: The lawsuit reveals that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals, resulting in shareholder losses.
Insider Trading Allegations: Insiders and affiliates are accused of using offshore or nominee accounts to facilitate coordinated stock dumping during a price inflation campaign, raising further concerns about corporate governance.
Disclosure Failures: Picard Medical's public statements and risk disclosures omitted any mention of false rumors and artificial trading activities, leading to investor misconceptions about the company's true financial condition, which could impact future investment decisions.

Biotech Stocks Pre-Market Trading Insights

Jun 03 2026NASDAQ.COM

Significant Pre-Market Gains: Picard Medical, Inc. (PMI) surged 34% to $0.36 in pre-market trading, indicating strong investor interest likely driven by positive clinical trial updates, which may attract further investment.
Other Gaining Stocks: Connect Biopharma Holdings Limited (CNTB) rose 14% to $2.44, while LifeVantage Corporation (LFVN) increased 10% to $9.46, suggesting an improving investor sentiment in the biotech sector that could enhance overall industry performance.
Pre-Market Decliners: TransCode Therapeutics, Inc. (RNAZ) fell 22% to $4.13, reflecting negative market reactions to recent news, which may lead investors to reassess its future prospects.
Market Sentiment Impact: The overall pre-market trading indicates volatility in biotech stocks, prompting investors to closely monitor clinical trial results and corporate developments to make more informed investment decisions.

Bluejay Diagnostics Partners with Argonaut, Shares Surge 100%

Jun 03 2026NASDAQ.COM

Bluejay Partnership: Bluejay Diagnostics Inc. (BJDX) has entered a strategic partnership with Argonaut Manufacturing Services to advance its Symphony platform, leading to a 100% surge in share price to $4.34 on Tuesday, reflecting strong market confidence in its innovative diagnostic technology.
Device Advantages: The Symphony platform can provide highly sensitive test results using just three drops of blood in about 20 minutes without additional reagents or sample preparation, significantly enhancing the simplicity and efficiency of clinical laboratory testing, which is expected to transform diagnostic practices in critical care.
Picard Medical Progress: Picard Medical Inc. (PMI) successfully completed animal implant studies for its next-generation artificial heart platform at the University of Arizona, resulting in a 60.33% increase in share price, showcasing its technological advancements and market potential in cardiac treatment.
Clinical Data Highlights: Legend Biotech Corp. (LEGN) will present promising preliminary Phase 1 data for LB2501 targeting relapsed/refractory B-cell non-Hodgkin lymphoma at the upcoming European Hematology Association Congress, demonstrating a 100% objective response rate, further solidifying its competitive position in the biopharmaceutical sector.